biomedicines

IMPACT FACTOR 3.9 | Indexed in: PubMed | CITESCORE 5.2

an Open Access Journal by MDPI

Discovery and Development of Constrained Peptide Ligands

Guest Editors:

Prof. Dr. Hiroaki Suga
Department of Chemistry, School of Science, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan

Dr. Toby Passioura
Department of Chemistry, School of Science, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan

Deadline for manuscript submissions:
closed (30 June 2018)

Message from the Guest Editors

Dear Colleagues,

Constrained peptide ligands often exhibit exquisite target affinity and selectivity, making them appealing candidates for novel drug discovery and development. Unlike smaller molecules, constrained peptides are capable of modulating protein–protein interactions, making them amenable to targeting the so-called "undruggabe" proteome. Additionally, the intermediate size of constrained peptides relative to small molecules and larger biologics (e.g., antibodies), means that constrained peptides can, in some cases, simultaneously exhibit the benefits of both, with small molecule-like pharmacology and antibody-like specificity and affinity.

We invite research and review papers in the fields of constrained peptide ligand discovery and development, including articles describing macrocyclic peptides, stapled peptides, disulfide constrained peptides, constrained peptide pharmacology and studies of constrained peptide structure–activity relationships.

Prof. Dr. Hiroaki Suga
Dr. Toby Passioura
Guest Editors

biomedicines

IMPACT FACTOR 3.9 | Indexed in: PubMed | CITESCORE 5.2

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
𝕏@Biomed_MDPI